BioQ Pharma
BioQ Pharma is a specialty pharmaceutical company dedicated to addressing unmet needs in infusion technology. Their proprietary invenious™ platform transforms infusible medicines into ready-to-use connect-and-go systems, making drug delivery safer, more effective, and simpler. They focus on developing innovative, safe, and efficient infusion systems that improve patient care and reduce costs. Their mission is to set a new standard of care in the presentation and administration of infusible pharmaceuticals, with a vision to enhance safety, efficacy, sterility, value, and convenience in drug infusion.
Industries
Nr. of Employees
small (1-50)
BioQ Pharma
Patents
Products
Prefilled ropivacaine single-use infusion product for post-surgical pain
Disposable, hermetically sealed, pre-filled unit-dose infusion system containing 0.2% ropivacaine for continuous peripheral nerve block and wound infiltration; intended for single-patient use and point-of-care activation.
Prefilled propofol infusion product with programmable flow and bolus
Pre-filled infusion presentation containing 1% propofol with programmable flow-rate and bolus capabilities, intended for sedation and ambulatory applications.
Prefilled sedation infusion product (AS-2)
An additional pre-filled ready-to-use infusion pharmaceutical (referred to as AS-2 in public materials) developed for sedation indications and included in licensing agreements.
invenious™/ propofol
A ready-to-use propofol pharmaceutical presentation designed to help providers increase patient throughput, while improving safety and sterility for patients.
Prefilled ropivacaine single-use infusion product for post-surgical pain
Disposable, hermetically sealed, pre-filled unit-dose infusion system containing 0.2% ropivacaine for continuous peripheral nerve block and wound infiltration; intended for single-patient use and point-of-care activation.
Prefilled propofol infusion product with programmable flow and bolus
Pre-filled infusion presentation containing 1% propofol with programmable flow-rate and bolus capabilities, intended for sedation and ambulatory applications.
Prefilled sedation infusion product (AS-2)
An additional pre-filled ready-to-use infusion pharmaceutical (referred to as AS-2 in public materials) developed for sedation indications and included in licensing agreements.
invenious™/ propofol
A ready-to-use propofol pharmaceutical presentation designed to help providers increase patient throughput, while improving safety and sterility for patients.
Services
End-to-end development and supply of self-contained, pre-filled infusion pharmaceuticals provided to pharmaceutical companies under license or supply agreements.
Support for regulatory submissions and quality system implementation to achieve certifications and approvals in multiple jurisdictions.
Management and coordination of third-party manufacturing and assembly partners to produce finished, pre-filled infusion products.
End-to-end development and supply of self-contained, pre-filled infusion pharmaceuticals provided to pharmaceutical companies under license or supply agreements.
Support for regulatory submissions and quality system implementation to achieve certifications and approvals in multiple jurisdictions.
Management and coordination of third-party manufacturing and assembly partners to produce finished, pre-filled infusion products.
Expertise Areas
- Infusion device and drug-device combination development
- Aseptic filling and unit-dose sterile packaging
- Regulatory compliance and submissions (ISO13485, CE, TGA)
- Quality systems and regulatory affairs
Key Technologies
- Unit-dose ready-to-use infusion systems
- Closed-system on-demand drug/diluent mixing
- Programmable flow and bolus infusion control
- Aseptic pre-filled sterile packaging
News & Updates
N. W. (Bill) Jasper Jr. was elected to the Board of Directors of BioQuiddity Incorporated in December 2013. He is a retired president and CEO of Dolby Laboratories and has extensive experience in corporate governance, finance, and technology transformation.
BioQuiddity and Lee's Pharmaceutical signed a strategic license and supply agreement for the registration and commercialization of BioQuiddity's ropivacaine and propofol infusion pharmaceutical products in China, Taiwan, Hong Kong, and Macau.
BioQuiddity appointed Daniel Tassé to its board of directors. He is a former CEO of Ikaria and has extensive experience in healthcare management and biotech.
BioQ Pharma expanded its license and supply agreement with Sandoz, a division of Novartis, to market an additional infusion pharmaceutical in the U.S.
BioQ Pharma and Cipla signed a strategic distribution, supply, and development agreement for the commercialization of BioQ's Ropivacaine infusion pharmaceutical in India.
BioQ Pharma announced it would present at the Needham Healthcare Conference in New York City.
N. W. (Bill) Jasper Jr. was elected to the Board of Directors of BioQuiddity Incorporated in December 2013. He is a retired president and CEO of Dolby Laboratories and has extensive experience in corporate governance, finance, and technology transformation.
BioQuiddity and Lee's Pharmaceutical signed a strategic license and supply agreement for the registration and commercialization of BioQuiddity's ropivacaine and propofol infusion pharmaceutical products in China, Taiwan, Hong Kong, and Macau.
BioQuiddity appointed Daniel Tassé to its board of directors. He is a former CEO of Ikaria and has extensive experience in healthcare management and biotech.
BioQ Pharma expanded its license and supply agreement with Sandoz, a division of Novartis, to market an additional infusion pharmaceutical in the U.S.
BioQ Pharma and Cipla signed a strategic distribution, supply, and development agreement for the commercialization of BioQ's Ropivacaine infusion pharmaceutical in India.
BioQ Pharma announced it would present at the Needham Healthcare Conference in New York City.